Dr. McGregor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6328
Summary
- Dr. Bradley McGregor is an oncologist in Boston, MA and is affiliated with Dana-Farber Cancer Institute. He received his medical degree from Tufts University School of Medicine and has been in practice 13 years. He specializes in genitourinary oncology and hematologic oncology.
Education & Training
San Antonio Uniformed Services Health Education ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2010- San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 2004 - 2007
Tufts University School of MedicineClass of 2004
Certifications & Licensure
CA State Medical License 2012 - Present
FL State Medical License 2022 - Present
ME State Medical License 2022 - 2026
OH State Medical License 2022 - 2026
RI State Medical License 2022 - 2026
VT State Medical License 2022 - 2026
CT State Medical License 2022 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Start of enrollment: 2017 Dec 28
- Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression Start of enrollment: 2019 Nov 27
Publications & Presentations
PubMed
- 126 citationsEnfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y. Yu, Daniel P. Petrylak, Peter H. O'Donnell, Jae-Lyun Lee, Michiel S. van der Heijden
The Lancet. Oncology. 2021-06-01 - 49 citationsLenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, ran...Toni K Choueiri, Masatoshi Eto, Robert Motzer, Ugo De Giorgi, Tomas Buchler
The Lancet. Oncology. 2023-03-01 - 245 citationsProgressive immune dysfunction with advancing disease stage in renal cell carcinomaDavid A. Braun, Kelly Street, Kelly P. Burke, David L. Cookmeyer, Thomas Denize
Cancer Cell. 2021-05-10
Journal Articles
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaPraful Ravi, Charlene Mantia, Christopher Su, Neeraj Agarwal, Yousef Zakharia, Rana R Mckay, Vivek Narayan, Ajjai Alva, Bradley A Mcgregor, David F Mcdermott, Toni K C..., JAMA Oncology
Authored Content
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients with Renal Cell CarcinomaMay 2020
Press Mentions
Trial Finds No Benefit of Adding Nivolumab to Tivozanib for Advanced Kidney CancerSeptember 14th, 2024- Fewer Adverse Effects with SBRT in Localized Prostate Cancer?February 21st, 2023
- Is a Diet Higher in Plant-Based Foods Associated with a Lower Risk of Prostate Cancer Progression and Recurrence?February 17th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
